A Phase I-Ii Clinical Trial of the Anti-Cd74 Monoclonal Antibody Milatuzumab in Frail Patients With Refractory Chronic Lymphocytic Leukaemia: A Patient Based Approach
British Journal of Haematology - United Kingdom
doi 10.1111/bjh.14726
Full Text
Open PDFAbstract
Available in full text
Categories
Date
May 3, 2017
Authors
Publisher
Wiley